Literature DB >> 1715330

Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts.

S Ghim1, N D Christensen, J W Kreider, A B Jenson.   

Abstract

BPV-1 induces focus formation in murine C127 cells and fibropapillomas in bovine fetal skin xenografts. In this study, we compared the specificity of neutralization of BPV-1 in both assay systems, using sera and monoclonal antibodies (MAbs) selected to define neutralizing epitopes. Sera from rabbits and cattle, inoculated with intact BPV-1 or PBV-2 virions, neutralize BPV-1 infectivity in both C127 cells and xenografts. Selected human sera and murine MAbs that react with intact BPV-1 particles, serum of a rabbit immunized with denatured BPV-1 particles, and sera from calves vaccinated with a recombinant LI fusion protein did not neutralize BPV-1 infection in either system. It was concluded that neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts by hyperimmune sera is specific and concordant for both assay systems, and involves conformational BPV-1 capsid epitopes.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1715330     DOI： 10.1002/ijc.2910490224

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  16 in total

1.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40, and -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft.

Authors:  N D Christensen; W A Koltun; N M Cladel; L R Budgeon; C A Reed; J W Kreider; P A Welsh; S D Patrick; H Yang
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Production of infectious bovine papillomavirus from cloned viral DNA by using an organotypic raft/xenograft technique.

Authors:  A A McBride; A Dlugosz; C C Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  The Rev protein of human immunodeficiency virus type 1 counteracts the effect of an AU-rich negative element in the human papillomavirus type 1 late 3' untranslated region.

Authors:  W Tan; S Schwartz
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; F Breitburd; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

6.  Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.

Authors:  Holly J Corbett; Germain J P Fernando; Xianfeng Chen; Ian H Frazer; Mark A F Kendall
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

7.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.

Authors:  R Kirnbauer; J Taub; H Greenstone; R Roden; M Dürst; L Gissmann; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Authors:  J A Suzich; S J Ghim; F J Palmer-Hill; W I White; J K Tamura; J A Bell; J A Newsome; A B Jenson; R Schlegel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

10.  Interaction of papillomaviruses with the cell surface.

Authors:  R B Roden; R Kirnbauer; A B Jenson; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.